These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 25181403

  • 21. Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin.
    Carriero D, Fabrizi F, Uriel AJ, Park J, Martin P, Dieterich DT.
    Int J Artif Organs; 2008 Apr; 31(4):295-302. PubMed ID: 18432584
    [Abstract] [Full Text] [Related]

  • 22. [Efficacy and safety of peginterferon alfa-2a and ribavirin treatment of chronic hepatitis C in the Republic of Serbia].
    Božić M, Bojović K, Fabri M, Nožić D, Trkulja B, Milošević I.
    Srp Arh Celok Lek; 2012 Apr; 140(7-8):448-55. PubMed ID: 23092029
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.
    Yamada G, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, Hayashi N, Sakai T.
    Clin Drug Investig; 2008 Apr; 28(1):9-16. PubMed ID: 18081356
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin.
    Nguyen MH, Trinh HN, Garcia R, Nguyen G, Lam KD, Keeffe EB.
    Am J Gastroenterol; 2008 May; 103(5):1131-5. PubMed ID: 18477343
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Pegylated interferon-α2a plus ribavirin for chronic hepatitis C in a real-life setting: the Hepatys French cohort (2003-2007).
    Bourlière M, Ouzan D, Rosenheim M, Doffoël M, Marcellin P, Pawlotsky JM, Salomon L, Fagnani F, Rouanet S, Pinta A, Vray M.
    Antivir Ther; 2012 May; 17(1):101-10. PubMed ID: 22267474
    [Abstract] [Full Text] [Related]

  • 32. Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4.
    Al Ashgar H, Helmy A, Khan MQ, Al Kahtani K, Al Quaiz M, Rezeig M, Kagevi I, Alshehri A, Al Kalbani A, Al Swat K, Dahab S, Elkum N, Al Fadda M.
    Ann Saudi Med; 2009 May; 29(1):4-14. PubMed ID: 19139619
    [Abstract] [Full Text] [Related]

  • 33. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.
    Myers RP, Benhamou Y, Bochet M, Thibault V, Mehri D, Poynard T.
    AIDS; 2004 Jan 02; 18(1):75-9. PubMed ID: 15090832
    [Abstract] [Full Text] [Related]

  • 34. Long-term pegylated interferon monotherapy following 72 weeks of pegylated interferon and ribavirin in hepatitis C virus genotype-1-infected slow responders.
    Watanabe S, Kobayashi Y, Kawata K, Noritake H, Chida T, Nagasawa M, Kageyama F, Kawamura K, Sasada Y, Suda T.
    Intern Med; 2015 Jan 02; 54(3):273-9. PubMed ID: 25748735
    [Abstract] [Full Text] [Related]

  • 35. Sustained Virologic Response to a Dual Peginterferon alfa-2a and Ribavirin in Treating Chronic hepatitis C Infection: A Retrospective Cohort Study.
    Naing C, Sitt T, Aung AT, Aung K.
    Medicine (Baltimore); 2015 Jul 02; 94(30):e1234. PubMed ID: 26222859
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Peginterferon still has a place in the treatment of hepatitis C caused by genotype 3 virus.
    Grando AV, Ferreira PRA, Pessôa MG, Mazo DFC, Brandão-Mello CE, Reuter T, Martinelli ALC, Gonzalez MP, Nastri ACS, Campos AF, Lopes MIBF, Brito JDU, Mendes-Corrêa MC.
    Rev Inst Med Trop Sao Paulo; 2017 Nov 06; 59():e67. PubMed ID: 29116287
    [Abstract] [Full Text] [Related]

  • 38. Treatment of chronic hepatitis C genotype 1 early responders with 36 week pegylated interferon and ribavirin therapy.
    Sood A, Midha V, Goyal O.
    Ann Hepatol; 2014 Nov 06; 13(5):503-9. PubMed ID: 25152982
    [Abstract] [Full Text] [Related]

  • 39. Low-dose pegylated interferon-α2a plus ribavirin therapy for elderly and/or cirrhotic patients with HCV genotype-1b and high viral load.
    Tamai H, Mori Y, Shingaki N, Kawashima A, Tsukuda H, Higashi K, Moribata K, Kawaguchi M, Ueda K, Deguchi H, Inoue I, Maekita T, Iguchi M, Kato J, Ichinose M.
    Antivir Ther; 2014 Nov 06; 19(1):107-15. PubMed ID: 24162072
    [Abstract] [Full Text] [Related]

  • 40. Efficacy of pegylated interferon plus ribavirin combination therapy for hepatitis C patients with normal ALT levels: a matched case-control study.
    Hiramatsu N, Inoue Y, Oze T, Kurashige N, Yakushijin T, Mochizuki K, Miyagi T, Tatsumi T, Kiso S, Kanto T, Kasahara A, Takehara T, Oshita M, Mita E, Hagiwara H, Inui Y, Katayama K, Tamura S, Yoshihara H, Imai Y, Hayashi N.
    J Gastroenterol; 2011 Nov 06; 46(11):1335-43. PubMed ID: 21858637
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.